Literature DB >> 22300656

Detection of ganciclovir resistance mutations by pyrosequencing in HCMV-infected pediatric patients.

Fabio Benzi1, Irene Vanni, Giulia Cassina, Elisabetta Ugolotti, Eddi Di Marco, Carmela Cirillo, Emilio Cristina, Giuseppe Morreale, Giovanni Melioli, Mauro Malnati, Roberto Biassoni.   

Abstract

BACKGROUND: Human cytomegalovirus (HCMV) is an opportunistic pathogen especially for immuno-suppressed subjects that might develop pharmacological resistance in patients undergoing prolonged antiviral treatment. Ganciclovir (GCV) is the drug used as first choice therapy in affected children and a GCV-resistant phenotype is mainly linked to mutations of the viral protein kinase UL97.
OBJECTIVES: Here a new quantitative pyrosequence (PSQ) method is presented that allows detection and quantification of the viral species carrying the more frequent UL97 mutations responsible for GCV resistance in clinical samples (>80% of known cases). STUDY
DESIGN: The system has been validated using two independent approaches (cloning and sequencing of UL-97 gene fragments and real-time PCR) and clinical samples derived from 3 pediatric patients.
RESULTS: The UL97 pyrosequencing analysis has indicated a significant increase of mutant viruses carrying the H520Q and C592G mutations. In particular, the H520Q viral mutation, known to increase GCV resistance (IC50=10) increased around 5 times during hospitalization. In addition, C592G (known to have IC50=2.9) also increased 3 times.
CONCLUSIONS: PSQ is a quick, cheap, high throughput and sensitive analysis method to detect GCV-associated resistance mutation useful to follow antiviral therapy in perinatal CMV-infection as well as in immune-suppressed patients.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22300656     DOI: 10.1016/j.jcv.2012.01.006

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  6 in total

1.  Detection of antiviral drug resistance in patients with congenital cytomegalovirus infection using long-read sequencing: a retrospective observational study.

Authors:  Yuka Torii; Kazuhiro Horiba; Jun-Ichi Kawada; Kazunori Haruta; Makoto Yamaguchi; Takako Suzuki; Hideko Uryu; Naoyuki Kashiwa; Keiji Goishi; Tomoo Ogi; Yoshinori Ito
Journal:  BMC Infect Dis       Date:  2022-06-22       Impact factor: 3.667

Review 2.  Emerging (val)ganciclovir resistance during treatment of congenital CMV infection: a case report and review of the literature.

Authors:  Beatriz Morillo-Gutierrez; Sheila Waugh; Ailsa Pickering; Terence Flood; Marieke Emonts
Journal:  BMC Pediatr       Date:  2017-08-22       Impact factor: 2.125

3.  Monocytes Latently Infected with Human Cytomegalovirus Evade Neutrophil Killing.

Authors:  Elizabeth Elder; Benjamin Krishna; James Williamson; Yusuf Aslam; Neda Farahi; Alexander Wood; Veronika Romashova; Kate Roche; Eain Murphy; Edwin Chilvers; Paul J Lehner; John Sinclair; Emma Poole
Journal:  iScience       Date:  2019-01-08

Review 4.  40 Years after the Registration of Acyclovir: Do We Need New Anti-Herpetic Drugs?

Authors:  Anna Majewska; Beata Mlynarczyk-Bonikowska
Journal:  Int J Mol Sci       Date:  2022-03-22       Impact factor: 5.923

5.  Assessment of the Human Cytomegalovirus UL97 Gene for Identification of Resistance to Ganciclovir in Iranian Immunosuppressed Patients.

Authors:  Hossein Keyvani; Sedigheh Taghinezhad Saroukalaei; Amir Hossein Mohseni
Journal:  Jundishapur J Microbiol       Date:  2016-05-29       Impact factor: 0.747

6.  Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis.

Authors:  Danielle B L Oliveira; Marika K Iwane; Mila M Prill; Geoffrey A Weinberg; John V Williams; Marie R Griffin; Peter G Szilagyi; Kathryn M Edwards; Mary A Staat; Caroline B Hall; Edison L Durigon; Dean D Erdman
Journal:  J Clin Virol       Date:  2015-01-24       Impact factor: 3.168

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.